ACRX - アセルRX・ファ―マシュ―ティカルズ (AcelRx Pharmaceuticals Inc.) アセルRX・ファ―マシュ―ティカルズ

 ACRXのチャート


 ACRXの企業情報

symbol ACRx
会社名 AcelRx Pharmaceuticals Inc (アセルRX・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AcelRx Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04 Zalviso which utilize sublingual sufentanil delivered through a non-invasive route of administration and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation anxiety reduction and pain relief for patients undergoing painful procedures in a physician''s office. It also includes ARX-02 which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.   アセルRX・ファ―マシュ―ティカルズは米国の医薬品会社。急性疼痛や突出痛用の治療薬の開発と商業化に重点を置く。候補薬には入院患者向け急性痛自己治療システム「Zalviso」、および救急処置室や救急病院用の中度・重度疼痛治療のスフェンタニルナノ粒子錠剤がある。本社はカリフォルニア州。   AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
本社所在地 351 Galveston Drive Redwood City CA 94063 USA
代表者氏名 Adrian Adams エイドリアンアダムス
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-216-3500
設立年月日 38534
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 41人
url www.acelrx.com
nasdaq_url https://www.nasdaq.com/symbol/acrx
adr_tso
EBITDA EBITDA(百万ドル) -31.00100
終値(lastsale) 2.99
時価総額(marketcap) 181193742.86
時価総額 時価総額(百万ドル) 160.58980
売上高 売上高(百万ドル) 3.38800
企業価値(EV) 企業価値(EV)(百万ドル) 215.42480
当期純利益 当期純利益(百万ドル) -10.92800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AcelRx Pharmaceuticals Inc revenues decreased 80% to $1.2M. Net loss decreased 23% to $22.1M. Revenues reflect Collaboration agreement revenue decrease of 88% to $625K Contract and other decrease of 2% to $536K. Lower net loss reflects Research and development - Balancing val decrease of 45% to $6M (expense) General and Administrative - Balancing v decrease of 6% to $6.8M (expense).

 ACRXのテクニカル分析


 ACRXのニュース

   AcelRx to Host Second Quarter 2020 Financial Results Call and Webcast on Monday, August 10th, 2020  2020/08/03 20:05:00 PR Newswire
REDWOOD CITY, Calif., Aug. 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 10, 2020. AcelRx management will host a live…
   AcelRx inks deal with Zimmer Biomet to distribute Dsuvia (NYSE:ZBH)  2020/07/23 13:23:11 Seeking Alpha
Zimmer Biomet's (NYSE:ZBH) Dental division has agreed to distribute AcelRx Pharmaceuticals' (NASDAQ:ACRX) Dsuvia (sufentanil sublingual tablet) within the
   AcelRx Pharmaceuticals : Announces Exclusive Distribution and Promotion Partnership for DSUVIA® | MarketScreener  2020/07/23 12:41:04 MarketScreener
REDWOOD CITY, Calif., July 23, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company, today announced an agreement to market DSUVIA®, a sublingual… | July 23, 2020
   AcelRx Announces $10 Million Common Stock Offering Priced At The Market  2020/07/23 08:30:00 Benzinga
REDWOOD CITY, Calif., July 23, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) (AcelRx), a specialty pharmaceutical company focused on the …
   La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer  2020/06/22 16:14:54 Benzinga
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction. Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals … Full story available on Benzinga.com
   La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer  2020/06/22 16:14:54 Benzinga
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction. Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals … Full story available on Benzinga.com
   The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset  2020/06/10 11:30:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Imara Inc (NASDAQ: IMRA ) IMMURON LTD/S ADR (NASDAQ: IMRN )( reacted to an award of a $3.7 million in DoD funding for a new candidate that offers protection against travelers' diarrhea) Inari Medical Inc (NASDAQ: NARI ) Keros Therapeutics Inc (NASDAQ: KROS ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) United Therapeutics Corporation (NASDAQ: UTHR ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 9) Applied Molecular Transport Inc (NASDAQ: AMTI ) (IPOed Friday) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Stocks In Focus Melinta Agrees To Take Tetraphase Private For $39M In Cash And $16M In CVRs With the two-way contest for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) ending after AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) pulled out, Melinta announced a definitive merger agreement to acquire Tetraphase, through a tender offer, for an aggregate of $39 million in cash, plus an additional $16 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.
   The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic  2020/06/04 12:13:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Fortress Biotech (NASDAQ: FBIO ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Pliant Therapeutics Inc (NASDAQ: PLRX ) (went public Wednesday) Protara Therapeutics Inc (NASDAQ: TARA ) Qiagen NV (NYSE: QGEN ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 3) Cellectar Biosciences Inc (NASDAQ: CLRB ) (priced a $20-million common stock offering) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Genfit SA (NASDAQ: GNFT ) Stocks In Focus Kezar Reports Positive Early Stage Results For KZR-616 In Systemic Lupus Erythematosus Kezar Life Sciences, Inc. (NASDAQ: KZR ) announced updated results from the Phase 1b portion of the Phase 1b/2 MISSION study, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus with and without nephritis, showing overall improvements across seven measures of disease activity.
   Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx  2020/05/28 00:55:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. (“Melinta”) amending its prior proposal to acquire the Company (the “Amended Melinta Proposal”), and has determined that the Amended Melinta P
   Tetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration  2020/05/27 13:25:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into an amendment to the Agreement and Plan of Merger, dated March 15, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. (“AcelRx”) and its merger subsidiary (the “Merger Agreement”), to increa
   AcelRx Pharmaceuticals Reports First Quarter 2020 Financial Results  2020/05/11 20:01:00 PR Newswire
REDWOOD CITY, Calif., May 11, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter…
   Bidding War Sends Tetraphase Shares Soaring  2020/05/07 16:55:11 Benzinga
Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged. Two-way Race The Watertown, Massachusetts-based company, which has a commercial antibiotic called Xerava to treat serious and life-threatening infections, is being pursued by La Jolla Pharmaceutical Company (NASDAQ: LJPC ) after it signed a definitive agreement to be acquired by AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) in mid-March. La Jolla revealed in a filing it submitted a non-binding offer to acquire 100% of the equity of Tetraphase in an all-cash transaction. La Jolla offered for Tetraphase $22 million in cash, plus an additional $12.5 million potentially payable under contingent value rights, or CVRs, to be issued in the transaction. A contingent value right is a derivative instrument, with its value depending on some future event. If the event occurs by the specified date, then a holder of the CVR will get a pre-determined payout, mostly in cash. "We are impressed with the growth potential of XERAVA and excited about …
   The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom to Join S&P 500  2020/05/07 11:41:00 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) (reacted to its first-quarter results and clinical pipeline update) AstraZeneca plc (NYSE: AZN ) ( announced FDA approval for label expansion for its Farxiga) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) Catalent Inc (NYSE: CTLT ) Cytosorbents Corp (NASDAQ: CTSO ) (reacted to its strong first-quarter results) DexCom, Inc. (NASDAQ: DXCM ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-quarter results) Horizon Therapeutics PLC (NASDAQ: HZNP ) (reacted to first-quarter results) I mara Inc (NASDAQ: IMRA ) Immunomedics, Inc. (NASDAQ: IMMU ) Immunovant Inc (NASDAQ: IMVT ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MacroGenics Inc (NASDAQ: MGNX ) (reacted to its first-quarter results and sell-side reactions to the results) Masimo Corporation (NASDAQ: MASI ) Meridian Bioscience, Inc.
   AcelRx Pharmaceuticals (ACRX) Expected to Beat Earnings Estimates: Should You Buy?  2020/05/06 16:30:38 Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?  2020/05/05 16:51:00 Zacks Investment Research
During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アセルRX・ファ―マシュ―ティカルズ ACRX AcelRx Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)